Study Ellipta Inhaler

STUDY DESCRIPTION

Inhalers did not contain active treatment.

Design7: A 28-day, open-label, placebo study designed to assess ease of use of the ELLIPTA inhaler in adult patients with asthma (n=250), among patients using the inhaler correctly on Day 28. Correct use was evaluated using instructions derived from the prescribing information for products delivered in the ELLIPTA inhaler. At enrollment, patients were allowed up to 3 attempts to demonstrate correct use (with training between attempts 1 and 2, and 2 and 3 if necessary), and all patients were able to demonstrate correct use. On Day 28, patients were evaluated for correct use in a single attempt without additional instruction. Ninety-eight percent demonstrated correct use. "Easy to use" was defined as a rating of very easy or easy on a 4-point scale (very easy, easy, difficult, very difficult).